fosizensertib   Click here for help

GtoPdb Ligand ID: 13806

Synonyms: compound 19 [WO2023018643A1]
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: The chemical structure for fosizensertib was derived from WHO proposed INN list 132 (Feb 2025), in which it is listed as a receptor-interacting serine/threonine protein kinase 1 (RIPK1) inhibitor. This generated a SMILES match via PubChem to a compound (19) claimed in patent WO2023018643A1 (AbbVie) [1]. This appears to be a phosphate prodrug, that is dephosphorylated in vivo, to the active metabolite compound 2. In the absence of formal structure disclosure (March 2025) we hypothesise that this is likely to be the INN for AbbVie's oral ulcerative colitis lead ABBV-668.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 9
Hydrogen bond donors 2
Rotatable bonds 9
Topological polar surface area 124.84
Molecular weight 490.4
XLogP 0.92
No. Lipinski's rules broken 0

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CN(C[C@H](CC1=CC=CC=C1)OP(=O)(O)O)C(=O)C2=CC(=CN=C2)C#CC3=CN(C(F)F)N=C3
Isomeric SMILES P(=O)(O[C@H](CN(C(=O)C=1C=NC=C(C1)C#CC=2C=NN(C2)C(F)F)C)CC3=CC=CC=C3)(O)O
InChI InChI=1S/C22H21F2N4O5P/c1-27(15-20(33-34(30,31)32)10-16-5-3-2-4-6-16)21(29)19-9-17(11-25-13-19)7-8-18-12-26-28(14-18)22(23)24/h2-6,9,11-14,20,22H,10,15H2,1H3,(H2,30,31,32)/t20-/m0/s1
InChI Key AJSWMXIMACDPCV-FQEVSTJZSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Cusack KP, Hoemann MZ, Kinsman DA, Osman S, Stambuli JP, Argiriadi MA, O'reilly C, Dexter H, Fordyce E, St.Gallay S. (2023)
Nicotinamide ripk1 inhibitors.
Patent number: WO2023018643A1. Assignee: Abbvie Inc.. Priority date: 08/08/2022. Publication date: 16/02/2023.